J Gynecol Oncol.  2022 Nov;33(6):e86. 10.3802/jgo.2022.33.e86.

Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective

• Li N
• Liu Q
• Tian Y
• Wu L

• KMID: 2537974
• DOI: http://doi.org/10.3802/jgo.2022.33.e86

Abstract

Over the last decade, clinical trials using various poly ADP ribose polymerase (PARP) inhibitors on patients with ovarian cancer have shown promising results. The introduction of PARP inhibitors has changed the treatment landscape and improved outcomes for patients with ovarian cancer. Fuzuloparib, developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd., is a novel orally available small molecule PARP inhibitor. By introducing the trifluoromethyl group into chemical structure, fuzuloparib exhibits higher stability and lower inter-individual variability than other PARP inhibitors. Several clinical trials (FZOCUS series and others) have been carried out to assess the efficacy and safety of fuzuloparib through different lines of treatments for advanced or recurrent ovarian cancer in both treatment and maintenance. Here, we present the most recent data from these studies, discuss current progress and potential future directions.

Keyword

PARP Inhibitor; Fuzuloparib; Ovarian Cancer; Maintenance Therapy